An emerging trend in STI Management: Antibiotic STI Post-Exposure Prophylaxis Prevalence and Determinants in Recent Surveys
Preprint
Abstract
Objectives: This study aimed to estimate the prevalence of antibiotic post-exposure prophylaxis (STI PEP) use among gay, bisexual and other men who have sex with men (GBMSM) in England, and to identify demographic and behavioural factors associated with STI PEP use among early adopters. Methods: We synthesised individual-level data from nine surveys conducted between 2019 and 2024. To harmonise variables that differed subtly across surveys, we generated composite indicators for STI diagnosis, chemsex, and condomless sex. Multiple imputation was used to address partial missingness; participants missing core sociodemographic data were excluded. The primary outcome was self-reported STI PEP use. We calculated the prevalence of use in each survey and assessed associations using mixed-effects logistic regression. Composite variables were included as random effects if they were found to have an interaction with survey. Results: Across nine surveys with 14,142 participants, STI PEP use prevalence ranged from 3.61% (95% confidence interval (CI): 2.78–4.68%) in RiiSH 2020 to 13.05% (11.85–14.36%) in RiiSH 2024. Use was higher among those aged 40–44 (adjusted odds ratio (aOR) = 1.26; 95% CI: 1.00–1.58) and lower in those under 25 (aOR = 0.56; 0.39–0.82) or over 65 (aOR = 0.64; 0.41–0.99), compared to ages 30–34. Transgender women (aOR = 3.87; 1.75–8.50), Black (aOR = 1.85; 1.34–2.56) and Asian (aOR = 1.43; 1.09–1.88) individuals, and people living with HIV (aOR = 3.40; 2.69–4.31) had higher odds of use, compared with cisgender male, White, and HIV negative individuals, respectively. Chemsex (aOR = 2.15; 1.80–2.56), condomless sex (aOR = 1.59; 1.32–1.92), and recent STI diagnosis (aOR = 1.83; 1.34–2.51) were also associated with use. Conclusion: STI PEP use was more common among those practising behaviours associated with higher STI risk. However, participation and sampling biases limit finding generalisability, particularly to underrepresented groups such as women, ethinic minorities and heterosexuals. This analysis will provide a baseline from which to estimate the impact of the recommendation of doxycycline for STI post-exposure prophylaxis in the UK.Keywords
This publication has 23 references indexed in Scilit:
- Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial designThe Lancet Infectious Diseases, 2024
- Doxycycline post-exposure prophylaxis could theoretically select for resistance to various antimicrobials in 19 pathobionts: an in silico analysisInternational Journal of Infectious Diseases, 2024
- Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in WomenNew England Journal of Medicine, 2023
- Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted InfectionsClinical Infectious Diseases, 2023
- Evaluating the global, regional, and national impact of syphilis: results from the global burden of disease study 2019Scientific Reports, 2023
- Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted InfectionsNew England Journal of Medicine, 2023
- Use of doxycycline prophylaxis among gay and bisexual men in MelbourneThe Lancet HIV, 2019
- Doxycycline Prophylaxis for Bacterial Sexually Transmitted InfectionsClinical Infectious Diseases, 2019
- Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trialThe Lancet Infectious Diseases, 2018
- Doxycycline in the management of sexually transmitted infectionsJournal of Antimicrobial Chemotherapy, 2017